



UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555-0001

May 2, 2019

Dr. Timothy Stenzel
Director, Office of In Vitro Diagnostics
and Radiological Health
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Via e-mail to Timothy.Stenzel@fda.hhs.gov

SUBJECT: U.S. NUCLEAR REGULATORY COMMISSION PUBLIC COMMENT PERIOD AND
MEETINGS ON DRAFT APPROACHES FOR TRAINING AND EXPERIENCE
REQUIREMENTS FOR RADIOPHARMACEUTICALS

Dear Dr. Stenzel,

The purpose of this letter is to inform you that the U.S. Nuclear Regulatory Commission (NRC) has published a notice in the *Federal Register* announcing a second public comment period and two additional public meetings on the NRC staff's evaluation of training and experience (T&E) requirements for administration of radiopharmaceuticals requiring a written directive.

The NRC first contacted you in a letter dated November 2, 2018, that described the staff's planned evaluation of the T&E requirements under Subpart E, "Unsealed Byproduct Material—Written Directive Required," of Title 10 of the *Code of Federal Regulations* (10 CFR) Part 35, "Medical Use of Byproduct Material." Specifically, the staff is evaluating: (1) whether it makes sense to establish tailored T&E requirements for different categories of radiopharmaceuticals, (2) how those categories should be determined, (3) what the appropriate T&E requirements would be for each category, and (4) whether those requirements should be based on hours of training and experience, or focused more on competency. Revising the T&E requirements could provide additional pathways for physicians to become authorized users for specific types of radiopharmaceuticals requiring a written directive.

The November 2, 2018 letter also announced an initial public comment period and public meetings on the NRC's current T&E regulations under 10 CFR 35, Subpart E. Since the end of the initial public comment period the NRC staff has developed several draft approaches regarding the T&E requirements. The enclosed *Federal Register* notice (FRN) was published on May 2, 2019 (84 FR 18874) and opened a 30-day public comment period for input from the medical community and members of the public on the staff's draft approaches and a series of specific questions about the draft approaches. The FRN contains instructions on how to submit written comments via the Federal rulemaking Web site, www.regulations.gov, using docket ID number NRC-2018-0230. The 30-day comment period ends on June 3, 2019. The FRN is also available at <https://federalregister.gov/d/2019-08996>.

In addition to accepting written comments using www.regulations.gov, the NRC will also be accepting oral comments during two public meetings scheduled for May 14, 2019 and

May 23, 2019. The May 14 meeting will be open to members of the public for in-person attendance at the NRC's headquarters in Rockville, MD, and both meetings will be accessible for remote participation by moderated bridge line and webinar. The NRC's public meeting Web site will be updated with meeting details at least 10 days before the meetings:

<https://www.nrc.gov/pmns/mtg>.

To participate in the meetings via webinar and moderated bridge line, you must register in advance using the following URLs:

- Tuesday, May 14, 2019, 1:00 – 4:00 p.m. EDT:
<https://attendee.gotowebinar.com/register/26839476715014924>
Bridge Line: 888-452-5182
Pass Code: 2649150
- Thursday, May 23, 2019, 10:00 a.m. – 12:00 p.m. EDT:
<https://attendee.gotowebinar.com/register/4099285410908048653>
Bridge Line: 888-452-5182
Pass Code: 7476312

Comments received on the FRN will help the staff determine advantages, disadvantages, and other considerations for the draft approaches. The staff will document their evaluation and provide options regarding the T&E requirements in a paper to the Commission planned for issuance in late fall 2019. Additional information on the staff's T&E evaluation can be found at <https://www.nrc.gov/materials/miau/med-use-toolkit/training-experience-evaluation.html>. If you have questions on this correspondence, please contact Ms. Sarah Lopas of my staff at (301) 415-6360 or Sarah.Lopas@nrc.gov.



Christian Einberg, Chief
Medical Safety and Events Assessment Branch
Division of Materials Safety, Security, State
and Tribal Programs
Office of Nuclear Material Safety
and Safeguards

Enclosure:

Federal Register notice (84 FR 18874)

NUCLEAR REGULATORY COMMISSION

[NRC-2018-0230]

**Draft Approaches for Addressing Training and Experience Requirements for
Radiopharmaceuticals Requiring a Written Directive**

AGENCY: Nuclear Regulatory Commission.

ACTION: Draft approaches for training and experience requirements; request for comment and notice of public meetings.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) would like input on draft approaches the staff has developed that would potentially revise the training and experience (T&E) requirements for radiopharmaceuticals requiring a written directive. The input will be used to determine whether regulatory changes to the NRC's T&E requirements for authorized users (AUs) are warranted and potential advantages, disadvantages, and other considerations associated with each approach.

DATES: Submit comments by June 3, 2019. Comments received after this date will be considered if it is practical to do so, but the NRC is only able to ensure consideration for comments received on or before this date. Two public meetings to solicit comments will be held on May 14, 2019 and May 23, 2019.

ADDRESSES: You may submit comments by any of the following methods:

- **Federal Rulemaking Web Site:** Go to <http://www.regulations.gov> and search for Docket ID **NRC-2018-0230**. Address questions about NRC docket IDs in regulations.gov to Jennifer Borges; telephone: 301-287-9127; e-mail: Jennifer.Borges@nrc.gov. For technical

questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- **Mail comments to:** Office of Administration, Mail Stop: TWFN-7-A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, ATTN: Program Management, Announcements and Editing Staff.

For additional direction on obtaining information and submitting comments, see “Obtaining Information and Submitting Comments” in the **SUPPLEMENTARY INFORMATION** section of this document.

FOR FURTHER INFORMATION CONTACT: Sarah Lopas, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; telephone: 301-415-6360, e-mail: Sarah.Lopas@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Obtaining Information and Submitting Comments

A. Obtaining Information

Please refer to Docket ID **NRC-2018-0230** when contacting the NRC about the availability of information for this action. You may obtain publicly-available information related to this action by any of the following methods:

- **Federal Rulemaking Web Site:** Go to <http://www.regulations.gov> and search for Docket ID **NRC-2018-0230**.

- **NRC’s Agencywide Documents Access and Management System (ADAMS):** You may obtain publicly-available documents online in the ADAMS Public Documents collection at <http://www.nrc.gov/reading-rm/adams.html>. To begin the search, select “[Begin Web-based ADAMS Search](#).” For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or by e-mail to

pdr.resource@nrc.gov. The ADAMS accession number for each document referenced is provided the first time that it is mentioned in the **SUPPLEMENTARY INFORMATION** section.

- **NRC's PDR:** You may examine and purchase copies of public documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852.

B. Submitting Comments

Please include Docket ID **NRC-2018-0230** in your comment submission. The NRC cautions you not to include identifying or contact information in comment submissions that you do not want to be publicly disclosed in your comment submission. All comment submissions are posted at <http://www.regulations.gov> and entered into ADAMS. Comment submissions are not routinely edited to remove identifying or contact information.

If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment into ADAMS.

II. Background

On August 17, 2017, the Commission issued a staff requirements memorandum (SRM), SRM-M170817 (ADAMS Accession No. ML17229B284) directing the staff to evaluate: (1) whether it makes sense to establish tailored T&E requirements for different categories of radiopharmaceuticals, (2) how those categories should be determined (such as by risks posed by groups of radionuclides or by delivery method), (3) what the appropriate T&E requirements would be for each category, and (4) whether those requirements should be based on hours of T&E or focused more on competency. In response to the SRM, the NRC staff documented its

initial results, status, and next steps related to this evaluation in SECY-18-0084, “Staff Evaluation of Training and Experience Requirements for Administering Different Categories of Radiopharmaceuticals in Response to SRM-M170817” (ADAMS Package Accession No. ML18135A276).

In SECY-18-0084, the staff concluded that it may be feasible to establish tailored T&E requirements however, additional outreach with the medical community was needed to determine whether and how to tailor those requirements. Revising the T&E requirements could provide additional pathways for physicians to become AUs for specific types of radiopharmaceuticals under 10 CFR 35.300, “Use of unsealed byproduct material for which a written directive is required.”

As part of the needed additional outreach discussed in SECY-18-0084, the NRC published a notice in the *Federal Register* on October 29, 2018 (83 FR 54380) requesting comments on the staff’s evaluation of the T&E requirements for radiopharmaceuticals under 10 CFR 35.300. The NRC held four public meetings on this topic and collected public comments through January 29, 2019. Public comments and meeting transcripts are available on the Federal Rulemaking Web site at <https://www.regulations.gov/> under Docket ID **NRC-2018-0230**. Following the conclusion of the initial public comment period, the staff developed several draft approaches to address the directions in SRM-M170817. The NRC is now interested in obtaining input on these draft approaches.

During the comment period between May 2, 2019 and June 3, 2019, the NRC will hold two public meetings to discuss the draft approaches in this document and accept oral comments on those draft approaches. Both public meetings will be available for remote participation by moderated bridge line and webinar and one meeting will also be open for in-person attendance at the NRC’s headquarters in Rockville, Maryland. The public meetings are scheduled for May 14, 2019 (webinar and in-person attendance) and May 23, 2019 (webinar-only). The public

meetings will be noticed on the NRC's public meeting Web site at least 10 calendar days before each meeting. Members of the public should monitor the NRC's public meeting Web site at <https://www.nrc.gov/pmns/mtg>. The NRC will also post the meeting notices on the Federal Rulemaking Web site at <https://www.regulations.gov/> under Docket ID **NRC-2018-0230**.

The NRC may post additional materials related to this document, including public comments, on the Federal Rulemaking Web site. The Federal Rulemaking Web site allows you to receive alerts when changes or additions occur in a docket folder. To subscribe: (1) Navigate to the docket folder **NRC-2018-0230**; (2) click the "Sign up for E-mail Alerts" link; and (3) enter your email address and select how frequently you would like to receive emails (daily, weekly, or monthly).

III. Draft Approaches for Comment

The NRC staff has developed the following draft approaches based on input received during the initial public comment period and the Advisory Committee on Medical Uses of Isotopes T&E subcommittee's report dated February 27, 2019 (ADAMS Accession No. ML19058A598). The NRC is requesting comments on the draft approaches, including potential advantages, disadvantages, and other considerations associated with each and whether some approaches could be revised, combined, or if more than one approach could be implemented. The NRC staff is also requesting input on specific questions associated with the approaches.

A. Status Quo

"Status Quo" presents no changes to the current T&E requirements for radiopharmaceuticals requiring a written directive under 10 CFR 35.300.

- **Question 1:** If the "Status Quo" is maintained, how should the NRC ready itself for the expected increase in number and complexity of future radiopharmaceuticals?

- **Question 2:** Is there a challenge with the current T&E requirements—such as concerns regarding patient access to radiopharmaceuticals—that should be addressed through a rulemaking?

B. Tailored Training and Experience Requirements

The four approaches under this section would modify the existing T&E requirements under 10 CFR 35.390, “Training for use of unsealed byproduct material for which a written directive is required.” The approaches described under Sections B.1, B.2, and B.3 would require a set amount of T&E tailored to the specific radiopharmaceuticals, and the “Emerging Radiopharmaceuticals” approach described under Section B.4 would tailor T&E requirements for each new radiopharmaceutical as they were developed, similar to the approach for regulating new technologies under 10 CFR 35.1000, “Other Medical Uses of Byproduct Material or Radiation from Byproduct Material.”

- **Question 3:** How should the complexity of the radiopharmaceutical administration protocol be considered in establishing the T&E requirements for the limited approaches described in Sections B.1 and B.2 below?

1. Limited AU for Alpha- or Beta-Emitting Radiopharmaceuticals

Under this approach, any physician could complete at least 400 hours of T&E to be authorized to administer any alpha- or beta-emitting radiopharmaceutical. The T&E would consist of 200 hours of classroom and laboratory training and a minimum of 200 hours of supervised work experience tailored to alpha- and beta-emitting radiopharmaceuticals. Preceptor attestation would be required.

- **Question 4:** How should the NRC categorize radiopharmaceuticals with mixed emissions?

2. Limited AU for Unit-Dose, Patient-Ready Radiopharmaceuticals

Under this approach, any physician could complete at least 400 hours of T&E to be

authorized to administer any unit-dose, patient-ready radiopharmaceutical. The T&E would consist of 200 hours of classroom and laboratory training and a minimum of 200 hours of supervised work experience tailored to unit-dose, patient-ready radiopharmaceuticals. Preceptor attestation would be required.

- **Question 5:** Under what conditions should a radiopharmaceutical be considered “patient ready” such that the T&E requirements could be tailored?

3. *Limited AU for Any One Parenteral Radiopharmaceutical*

Under this approach any physician could complete at least 400 hours of T&E to be authorized to administer any one parenteral radiopharmaceutical. The T&E would consist of 200 hours of classroom and laboratory training and a minimum of 200 hours of supervised work experience tailored to the radiopharmaceutical they wish to administer. Preceptor attestation would be required. Limited AUs who have initially completed their at least 400 hours of T&E and then wish to administer a different radiopharmaceutical would be required to complete, minimally, an additional 80 hours of tailored, supervised work experience for each additional radiopharmaceutical.

4. *Emerging Radiopharmaceuticals*

Like the NRC’s regulations at 10 CFR 35.1000, under this approach the NRC would conduct individual reviews of each new emerging radiopharmaceutical to determine T&E requirements specific to the new radiopharmaceutical. The T&E requirements could be tailored to consider potential users of the radiopharmaceutical (e.g., non-nuclear medicine or non-radiation oncology physicians wishing to administer the radiopharmaceutical for their patients with indicated cancers), thus creating alternate T&E pathways for each new radiopharmaceutical.

C. Performance-Based

The approaches described in this section would remove prescriptive T&E requirements from the regulations and instead would focus oversight on the performance-based aspects of a licensee's medical program for the administration of radiopharmaceuticals.

1. Competency-Based Evaluation

Under this approach, proposed AUs would be required to demonstrate competency in radiation safety topics and radiation safety-related job duties through a formal competency evaluation (e.g., an examination or preceptor attestation).

- **Question 6:** How could a competency-based evaluation ensure appropriate training and experience for AUs administering radiopharmaceuticals?

2. Credentialing of Authorized Users

Under this approach, the NRC would no longer review and approve T&E qualifications for all AUs under 10 CFR part 35. Instead, licensees would develop and use their own policies and procedures to make self-determinations of whether their credentialed physicians have the appropriate T&E to be an AU for one or more radiopharmaceuticals under 10 CFR 35.300. Licensees would be required to maintain a training program that ensures compliance with the requirements in 10 CFR 35.41, "Procedures for administrations requiring a written directive," and 10 CFR part 20, "Standards for Protection Against Radiation."

- **Question 7:** How could physicians in small practices be credentialed (e.g., physicians not associated with hospitals or other large institutions and their credentialing boards)?

D. Team-Based

Team-based approaches could remove prescriptive T&E requirements for AUs, focus training requirements on the competency of the entire team, or revise the current 700-hour T&E

requirement for AUs based on pairing the AU with another individual with expertise in administering radiopharmaceuticals.

- **Question 8:** How should the AU's radiation safety responsibilities be clearly distinguished from other members of the team?

1. *Radiopharmaceutical Team*

Licensees would need a team to administer radiopharmaceuticals under 10 CFR 35.300. The team would minimally consist of an AU, a radiation safety officer, and a nuclear medicine technologist. Additional team members could include an authorized medical physicist, a health physicist, an authorized nuclear pharmacist, and other physicians that manage patient care. The T&E for the radiopharmaceutical team approach would be performance-based: licensees would develop policies and procedures to address how their teams would meet the requirements in 10 CFR 35.41 and 10 CFR part 20.

2. *Team AUs with Authorized Administrators*

Licensees would need both an AU and an authorized administrator (AA) to administer radiopharmaceuticals under 10 CFR 35.300. AAs would be individuals authorized by the licensee to administer radiopharmaceuticals in accordance with the written directive (e.g., a nuclear medicine technologist or a nuclear medicine advanced associate). The T&E for AUs would be performance-based and focus on the licensee's policies and procedures for written directives, reporting medical events, and patient release criteria. Because AAs would be physically administering radiopharmaceuticals, AAs would be required to have training on radiation safety, written directives, preparation and administration protocols (or vendor training, if available), patient release criteria, and medical event reporting.

3. *Partner Limited-Trained AUs with Authorized Nuclear Pharmacists*

The T&E for AUs would be at least 400 hours, however, the AU would be required to physically partner with an authorized nuclear pharmacist (ANP) for all administrations of radiopharmaceuticals. Unlike the approaches in Sections D.1 and D.2 above, prescriptive T&E would be required for the AU in this approach due to the AU's more prominent role in the administration of radiopharmaceuticals. The minimum of 400 hours of T&E for the physician partnering with an ANP would be focused on supervised work experience and patient cases, and preceptor attestation would be required. The AU would be responsible for administration of radiopharmaceuticals in accordance with the written directive, and the ANP would be responsible for radiation safety-related duties.

- **Question 9:** How should the radiation safety responsibilities be divided between the AU and ANP?

IV. Additional Questions for Consideration

The NRC is requesting input on the following questions as they relate to the draft approaches discussed above.

- **Question 10:** What are the advantages and disadvantages of the draft approaches?
- **Question 11:** Are there significant costs or benefits associated with any of the approaches?
- **Question 12:** Would any of the draft approaches impact patient access to radiopharmaceuticals or address stakeholder concerns of overly burdensome (regulatory) requirements?
- **Question 13:** For the draft approaches that consider tailored hours of T&E, what are the appropriate numbers of hours and what radiation safety topics should comprise the limited T&E?

- **Question 14:** Should the NRC consider inclusion of a formal radiation safety competency assessment and periodic reassessments for any of the draft approaches above? If so, who should establish and administer these assessments?
- **Question 15:** How would the draft approaches impact the medical organizations that use the NRC's T&E requirements as a basis for establishing their training programs?
- **Question 16:** Are there concerns regarding implementation and/or viability for any of the approaches discussed above?
- **Question 17:** Are there any unintended consequences of the draft approaches?
- **Question 18:** Which of the draft approaches best positions the NRC to effectively regulate future radiopharmaceuticals?
- **Question 19:** Should the NRC continue to play a role in the review and approval of AUs?

Dated at Rockville, Maryland, this 29th day of April 2019.

For the Nuclear Regulatory Commission.

/RA/

Andrea L. Kock, Director,
Division of Materials Safety, Security,
State, and Tribal Programs,
Office of Nuclear Material Safety
and Safeguards.

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

	First Name	Last Name	Company Name	Address Line 1	Address Line 2	City	State	ZIP Code
Dr.	Timothy	Stenzel	Director, Office of In Vitro Diagnostrics and Radiological Health	Food and Drug Administration	10903 New Hampshire Avenue	Silver Spring	MD	20993
Ms.	Kathleen	Cantwell	Director, Office of Strategic Operations and Regulatory Affairs	Centers for Medicare & Medicaid Services	7500 Security Boulevard	Baltimore	MD	21244
Ms.	Amy	Wride-Graney	American Board of Health Physics	1313 Dolley Madison Blvd., Suite 402		McLean	VA	22101
Ms.	Tomi	Papanikolaou	Executive Director, American Board of Medical Physics	P.O. Box 780518		San Antonio	TX	78278
Ms.	Valerie P.	Jackson	Executive Director, American Board of Radiology	5441 E. Williams Circle		Tucson	AZ	85711-7412
Dr.	Daniel	Pryma	Chair, American Board of Nuclear Medicine	4555 Forest Park Blvd., Suite 119		St. Louis	MO	63108-2173
Mr.	Stephen	Heinig	Office of Government Relations	Association of American Medical Colleges	655 K St. NW	Washington	DC	20001
Dr.	Greg	Beavers	Executive Director, American Board of Science in Nuclear Medicine	1037 N. Main St.		Kernersville	NC	27284
Ms.	Dawn	Edgerton	Director of Cardiovascular Imaging	Certification Board of Nuclear Cardiology	1401 Rockville Pike, Suite 600	Rockville	MD	20852
Dr.	Mitchell B.	Pace	Chair, American Osteopathic Board of Radiology	142 E. Ontario St.		Chicago	IL	60611-2864

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

Dr.	T. Bryson	Struse	Chair, American Osteopathic Board of Nuclear Medicine	142 E. Ontario St., Fl. 4		Chicago	IL	60611
Ms.	Nancy	Barrett	Executive Director, Canadian College of Physicists in Medicine	300 March Rd., Suite 202		Kanata	Ontario	K2K 2E2
Mr.	William M.	Ellis	Board of Pharmacy Specialities	2215 Constitution Ave. NW		Washington	DC	20037-2985
Dr.	Eric A.	Orzeck	Chair, Certification Board of Nuclear Endocrinology	245 Riverside Ave., Suite 200		Jacksonville	FL	32202
Dr.	Patricia M.	Conolly	American Board of Internal Medicine	510 Walnut St., Suite 1700		Philadelphia	PA	19106
Dr.	Gerald H.	Jordan	Executive Secretary, American Board of Urology	600 Peter Jefferson Parkway, Suite 150		Charlottesville	VA	22911
			Nuclear Medicine Technology Certification Board	3558 Habersham at Northlake Rd.		Tucker	GA	30084-4009
			Thyroid Cancer Survivors' Association, Inc.	P.O. Box 1102		Olney	MD	20830-1102
Dr.	Richard C.	Wender	Chief Cancer Control Officer	American Cancer Society	250 Williams St. NW	Atlanta	GA	30303
Dr.	Alan J.	Balch	Chief Executive Officer	Patient Advocate Foundation	421 Butler Farm Rd.	Hampton	VA	23666
			National Patient Advocate Foundation					
Dr.	George	Sledge, Jr.	Chief Scientific Advisor	Susan G. Komen	5005 LBJ Freeway, Suite 526	Dallas	TX	75244
Ms.	Karuna	Jaggar	Executive Director	Breast Cancer Action	275 Fifth St., Suite 307	San Francisco	CA	94103

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

			The Leukemia & Lymphoma Society		3 International Dr., Suite 200	Rye Brook	NY	10573
Ms.	Leah	Eshraghi	Dr. Susan Love Research Foundation	16133 Ventura Boulevard	Suite 1000	Encino	CA	91436
			Kidney Cancer Association	9450 SW Gemini Dr. #38269		Beaverton	OR	97008-7105
Ms.	Patricia J.	Goldsmith	Chief Executive Office	CancerCare	275 Seventh Ave.	New York	NY	10001
			Pancreatic Cancer Action Network	1050 Connecticut Ave. NW, Suite 500		Washington	DC	20036
			Sarcoma Alliance	775 Blithedale Ave., #334		Mill Valley	CA	94941
			Sarcoma Foundation of America	9899 Main St., Suite 204		Damascus	MD	20872
Dr.	Cheryl	Healton	Board Chair	Lung Cancer Alliance	1700 K St. NW, Suite 660	Washington	DC	20006
			The Lymphoma Research Foundation	Wall Street Plaza	88 Pine St., Suite 2400	New York	NY	10005
Mr.	Michael J.	Guastella	Council on Radionuclides and Radiopharmaceuticals, Inc.	500 North Capitol St. NW, Suite 210		Washington	DC	20001-7407
Mr.	Joseph W.	Turgeon	President and CEO	Spectrum Pharmaceuticals	11500 S. Eastern Ave., #240	Henderson	NV	89052
Mr.	Shaemus	Gleason	Bayer HealthCare Pharmaceuticals Inc.	Oncology SBU	100 Bayer Blvd.	Whippany	NJ	07981
Mr.	John	Witkowski	United Pharmacy Partners	5400 Laurel Springs Parkway		Suwanee	GA	30024
			Cardinal Health	7000 Cardinal Place		Dublin	OH	43017

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

			GE Healthcare	945 N. Edgewood Ave., #A1		Wood Dale	IL	60191
			Lantheus Medical Imaging, Inc.	331 Treble Cove Rd.		North Billerica	MA	01862
Ms.	Rachel	Semon	Advanced Accelerator Applications	The Empire State Building	350 Fifth Ave., Suite 6902	New York	NY	10118
Ms.	Cindy	Tomlinson	Senior Patient Safety and Regulatory Affairs Manager	American Society for Radiation Oncology	251 18th St. South, 8th Fl.	Arlington	VA	22202
Ms.	Caitlin B.	Kubler	Associate Director, Health Policy and Regulatory Affairs	Society of Nuclear Medicine and Molecular Imaging	1850 Samuel Morse Drive	Reston	VA	20190
Ms.	Tina	Getachew	Program Specialist, Government Relations	American College of Radiology	505 9th St. NW, Suite 910	Washington	DC	20004
			American Association of Physicists in Medicine	1631 Prince Street		Alexandria	VA	22314
			American Brachytherapy Society	11130 Sunrise Valley Dr., Suite 350		Reston	VA	20191
			Health Physics Society	950 Herndon Parkway, Suite 450		Herndon	VA	20170
Ms.	Ruth	McBurney	Executive Director	Conference of Radiation Control Program Directors	1030 Burlington Lane, Suite 4B	Frankfort	KY	40601
			American Thyroid Association	6606 Leesburg Pike, Suite 550		Falls Church	VA	22401

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

			American Society of Nuclear Cardiology	9302 Lee Highway, Suite 1210		Fairfax	VA	22301
			American College of Nuclear Medicine	1850 Samuel Morse Drive		Reston	VA	20190
			American Society of Hematology	2021 L St. NW, Suite 900		Washington	DC	20036
			American Society of Clinical Oncology	2318 Mill Rd., Suite 800		Alexandria	VA	22314
			American Nurses Association	8515 Georgia Ave., Suite 400		Silver Spring	MD	20910-3492
			American Association of Nurse Practitioners	Office of Government Affairs	1400 Crystal Drive, Suite 540	Alexandria	VA	22202
			Dana-Farber Cancer Institute	Radiation Oncology Training and Fellowship Program	450 Brookline Avenue	Boston	MA	02215-5450
Dr.	Robert	Miletich	Interim Chair and Professor	University at Buffalo, Department of Nuclear Medicine	105 Parker Hall, 3435 Main St.	Buffalo	NY	14214
			University of Findlay, Nuclear Medicine Institute	1000 N. Main St.		Findlay	OH	45840
Ms.	Jacqueline	Cross	Medical Training Coordinator	Johns Hopkins University	601 N. Caroline St., Suite 3233	Baltimore	MD	21287
Dr.	Angela	Bires	Nuclear Medicine Technology Program Director	School of Nursing and Health Sciences, Robert Morris University	6001 University Blvd.	Moon Township	PA	15108

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

Dr.	Kraig	Chugg	Department Chair	Department of Health Sciences, Weber State University	Marriott Health Sciences Building, Room 363F, 3875 Stadium Way, Dept. 3909	Ogden	UT	84408-3909
Dr.	Kyle P.	Meyer	Dean, College of Allied Health Professions	University of Nebraska Medical Center	42nd and Emile	Omaha	NE	68198
Dr.	William R.	Law	Dean, College of Science	c/o Nuclear Medicine Disciplines, Benedictine University	5700 College Road	Lisle	IL	60532
Dr.	Dinko	Franceschi	Division Chief, Nuclear Medicine	Stony Brook University Hospital	101 Nicolls Road	Stony Brook	NY	11794
Ms.	Kellee	George	Program Director, KU Nuclear Medicine Technology	Department of Respiratory Care and Diagnostic Science, University of Kansas	3901 Rainbow Blvd.	Kansas City	KS	66160
Dr.	Scott R.	Sechrist	Associate Professor, Medical Diagnostic & Translational Sciences	Old Dominion University	2128 Health Sciences Building	Norfolk	VA	23529
Mr.	Joseph	Hawkins	Program Director, Nuclear Medicine Technology	Adventist University of Health Sciences	671 Winyah Drive	Orlando	FL	32803
Dr.	Emogene	Fox	Professor and Chairperson	Department of Health Sciences, University of	201 Donaghey Ave.	Conway	AR	72035

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

				Central Arkansas				
			Baptist Health College Little Rock	School of Nuclear Medicine Technolgy	11900 Colonel Glenn Road	Little Rock	AR	72210- 2820
Dr.	Richard	Hoylman	Program Director, Nuclear Medicine and Molecular Imaging Technology	Oregon Institute of Technology	3201 Campus Drive	Klamath Falls	OR	97601
			South College	School of Health and Therapy	3904 Lonas Drive	Knoxville	TN	37909
			Baptist College of Health Sciences	Department of Nuclear Technology Medicine	1003 Monroe Avenue	Memphis	TN	38104
Dr.	Gerhild	Packert	Department of Medical Technology	College of Nursing and Health Sciences, Barry University	11300 NE 2nd Ave.	Miami Shores	FL	33161- 6695
Dr.	Norman E.	Bolus	Program Director, Assistant Professor	Nuclear Medicine Technology, University of Alabama at Birmingham	1705 University Blvd.	Birmingham	AL	35294
			Roosevelt University	Nuclear Medicine Technology, College of Arts and Sciences	430 S. Michigan Ave.	Chicago	IL	60605
			Lewis University	Nuclear Medicine Technology,	1 University Parkway	Romeoville	IL	60446

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

				College of Arts and Sciences				
Ms.	Crystal	Botkin	St. Louis University	Nuclear Medicine Technology	Allied Health Building, 3437 Caroline St., 3004	St. Louis	MO	63104
Dr.	Richard M.	Kliman	Cedar Crest College, Chair, Department of Biological Sciences	c/o Nuclear Medicine Technology	100 College Drive	Allentown	PA	18104
Dr.	Gary	Marano	Nuclear Medicine Preceptor	West Virginia University, Ruby Memorial Hospital	1 Medical Center Drive	Morgantown	WV	26505
Dr.	David	Gilmore	Program Director & Associate Professor, Nuclear Medicine Technology	Massachusetts School of Pharmacy and Health Sciences	179 Longwood Ave.	Boston	MA	02115
Dr.	Vesper	Grantham	Program Director, Nuclear Medicine	Department of Medical Imagings and Radiation Sciences, College of Allied Health, The University of Oklahoma Health Sciences Center	1200 North Stonewall Ave.	Oklahoma City	OK	73126-0901
Dr.	Paula	Deming	Endowed Professor of Health Sciences, Chair, Department of Medical Laboratory and Radiation Sciences	College of Nursing and Health Sciences, University of Vermont	302B Rowell Building	Burlington	VT	05405

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

Ms.	Terri	Mosley	Program Coordinator and Advisor, Department of Radiation and Technology	Loma Linda University, School of Allied Health Professions	Nichol Hall A829	Loma Linda	CA	92350
Dr.	Ryan	Fisher	Chair, Department of Biology, Nuclear Medicine Technology Concentration	Salem State University	352 Lafayette St.	Salem	MA	01970
			Thomas Jefferson University	Jefferson College of Health Professions	Edison Building, 130 S. Ninth St., Suite 100	Philadelphia	PA	19107
Prof .	Miriam	Espada Caro	University of Puerto Rico, Medical Sciences Campus	School of Health Professions Main Building, 7th Fl., Office #723		Monacillo Area, Rio Piedras	PR	
Dr.	J. Lynne	Williams	Nuclear Medicine Technology, Department of Clinical and Diagnostic Sciences	Oakland University	433 Meadow Brook Rd.	Rochester	MI	48309-4452
Dr.	Matthew	Foradori	Professor & Director of Medical Technology & Nuclear Medicine Technology	Department of Biology and Health Services, Edinboro University of Pennsylvania	Cooper Hall, 127B, 219 Meadville St.	Edinboro	PA	16444
Ms.	Peggy	Fortsch	Dean, School of Health Sciences	Radiography Program Director, Professor, Allen College	1825 Logan Avenue	Waterloo	IA	50703

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

Ms.	Elizabeth	Hodgson	Coordinator, Nuclear Medicine Technology	York College of Pennsylvania	Appell Life Sciences, Room 224, 444 Country Club Rd.	York	PA	17403-3651
Dr.	Kayla	Valentino	Chair, Radiological & Health Professions	Manhattan College	4513 Manhattan College Parkway	Riverdale	NY	10471
Dr.	Stevee	McIntyre	Program Coordinator, Radiologic Sciences Program	University of New Mexico	1 University of New Mexico	Albuquerque	NM	87131-0001
Dr.	Elias R.	Melhem	Chair, Dept. of Diagnostic and Radiology & Nuclear Medicine	University of Maryland School of Medicine	655 W. Baltimore St.	Baltimore	MD	21201
Dr.	Marc	Fischer	Nuclear Medicine Technology, Dept. of Allied Health Sciences	Molloy College	1000 Hempstead Ave., Casey Building Room 10A	Rockville Centre	NY	11571-5002
Dr.	Gerald	Dodd	University of Colorado Denver, Nuclear Medicine	Leprino Building, Dept. of Radiology, MS L954	12401 E. 17th Ave.	Aurora	CO	80045
Dr.	Martin	Charron	Virginia Commonwealth University Medical Center	School of Medicine, Dept. of Radiology	1200 E. Broad St., West Hospital, Room 2-013	Richmond	VA	23298
Dr.	Gary R.	L'Abbe	Regis College	Medical Imaging, Nuclear Medicine Technology Concentration	235 Wellesley St.	Weston	MA	02493

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

Dr.	Jeff	Galen	Program Director, Nuclear Medicine	University of Missouri	611 Lewis Hall, 701 S. 5th St.	Columbia	MO	65211
Dr.	Otto	Casal	Radiology Tech Administrator	Department of Radiology, University of Utah	30 North 1900 East	Salt Lake City	UT	84132
			Joint Review Committee on Educational Programs in Nuclear Medicine Technology	820 W. Danforth Rd., #B1		Edmond	OK	73003
			University of Arkansas College of Pharmacy	College of Pharmacy, Dean's Office, University of Arkansas of Medical Sciences	4301 W. Markham St.	Little Rock	AR	72205
Dr.	Miguel	Hernandez Pampaloni	Associate Professor, Chief of Nuclear Medicine, Director, Nuclear Medicine Residency & Fellowship Programs	University of California San Francisco	505 Parnassus Ave.	San Francisco	CA	94117
Dr.	Mark	King	Associate Professor of Radiology, Diagnostic Radiology Program Director	Associate Program Director Interventional Radiology, The Ohio State University Wexner Medical Center	410 W. 10th Ave.	Columbus	OH	43210
Dr.	Lilja	Bjork Solnes	Program Director, Diagnostic Radiology Residency, Assistant	Johns Hopkins Medicine - White Marsh	4924 Campbelle Boulevard	Nottingham	MD	21236

Distribution List for the Training and Experience *Federal Register* Notice (84 FR 18874)

			Professor of Radiology and Radiological Science					
			Association for Program Directors in Radiology		820 Jorie Boulevard	Oak Brook	IL	60523
Dr.	Jennifer	Scheler	Assistant Professor of Radiology	Department of Radiology, University of Cincinnati Medical Center	234 Goodman St.	Cincinnati	OH	45219
Mr.	Richard	Anderson	Radiation Safety Office, UC Health	University of Cincinnati Medical Center	234 Goodman St.	Cincinnati	Oh	45219